Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24430116 | 0.86 | ALDH1A1 (0.53) | MEN1KMT2AKDM4EALDH1A1HSD17B3 | |
| SCHEMBL24430113 | 0.85 | MEN1 (0.54) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL24430081 | 0.85 | MEN1 (0.48) | MEN1KMT2AKDM4EALDH1A1HSD17B3 | |
| SCHEMBL24430026 | 0.84 | KMT2A (0.52) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL24429997 | 0.84 | ALDH1A1 (0.46) | MEN1KMT2AKDM4EALDH1A1HSD17B3 | |
| SCHEMBL24437318 | 0.84 | RPS6KA3 (0.47) | MEN1KMT2AKDM4EALDH1A1HSD17B3 | |
| SCHEMBL24430114 | 0.82 | MEN1 (0.68) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL24430074 | 0.82 | MEN1 (0.50) | MEN1KMT2AKDM4EALDH1A1POLB | |
| SCHEMBL24430079 | 0.82 | MEN1 (0.45) | MEN1KMT2AKDM4EALDH1A1HSD17B3 | |
| SCHEMBL24430013 | 0.82 | MEN1 (0.49) | MEN1KMT2AKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339860-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | SOUTHERN RES INST (US) | 2023-10-26 | — | — | US | disclosed |
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | Southern Reserach Institute (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | Southern Reserach Institute (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2022109066-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE AND CHRONIC KIDNEY DISEASE | SOUTHERN RESEARCH INSTITUTE (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20220153695-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153695-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | HMOX1, GLS, HMOX2 | MEN1 4171/4885KMT2A 2088/4885KDM4E 960/4885 |
| US-20230339860-A1 | Compounds for the Treatment Of Acute and Chronic Kidney Disease | HMOX1, HMOX2, GLS | MEN1 4651/4885KMT2A 2904/4885KDM4E 2869/4885 |
| US-11753374-B2 | Compounds for the treatment of acute and chronic kidney disease | HMOX1, GLS, HMOX2 | MEN1 4171/4885KMT2A 2088/4885KDM4E 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.